Published in Medical Letter on the CDC and FDA, June 19th, 2005
The timing of the strategic business update is the result of nebivolol's Prescription Drug User Fee Act (PDUFA) date, which is currently scheduled for May 31, 2005. Mylan is also scheduling a non-deal investor roadshow following the strategic business update.
"We are pleased that we were able to achieve the high end of our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.